Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Off-label use of gabapentin and pregabalin for anxiety

Wallace B. Mendelson, MD
Meds
July 31, 2019
Share
Tweet
Share

An excerpt from Understanding Medicines for Anxiety.

In addition to medicines with FDA indications for anxiety, such as benzodiazepines and some antidepressants, a number of drugs are frequently prescribed off-label. Among these are gabapentin and the related compound pregabalin, collectively known as gabapentinoids.  Their popularity is remarkable: gabapentin has been the tenth most commonly prescribed medicine in the U.S., and equally remarkable is that up to 95 percent of its prescriptions are for uses for which it does not carry an approved indication.  Similarly, in terms of sales, pregabalin is the fourth most commonly used drug among those typically found in primary care settings.  Although much of this prescribing is for pain, a significant amount appears to be related to anxiety.  In this article we will review this particular use, beginning with some background.

Gabapentin (Neurontin) and pregabalin (Lyrica) are anticonvulsants and nerve pain medicines which have structural similarities to the inhibitory neurotransmitter GABA. Gabapentin was developed in 1993 and has indications for shingles (‘postherpetic neuralgia’) and partial-onset seizures. It has had a growing popularity in off-label uses for fibromyalgia, pain from a variety of causes, migraine, cocaine withdrawal, anxiety, and insomnia. A related compound, gabapentin encarbil (Horizant), is approved for shingles and restless leg syndrome. Pregabalin was developed in 2004 and is approved for nerve pain from diabetes and spinal cord injuries, fibromyalgia, and adjunctive treatment of partial-onset seizures. Although prescribed off-label for anxiety in the U.S., it is approved for this purpose in the U.K., where it is sometimes called the ‘new Valium’.

Studies in animal models of anxiety have shown some benefit of gabapentin, but there are minimal systematic studies in humans. One showed benefits in social phobia, another showed no benefit in panic or agoraphobia in the overall group, although some individual patients were helped. There has been a report of improvement in anxiety and hot flashes in breast cancer patients. Some studies have reported improvement in pre-surgical anxiety. Overall, though, there are little systematic data on persons with generalized anxiety disorder (GAD). Most studies of pregabalin for GAD have shown some reduction in anxiety, though with one exception the duration of treatment was eight weeks or less. One study reported that treatment over a six-month period was more effective than placebo in preventing a return of symptoms. There are some data that it might be helpful as an augmenting medicine in persons who have not responded to antidepressants for generalized anxiety disorder.

Side effects: The most common side effects of gabapentin are somnolence (19%), dizziness (17%), and ataxia (13%). Uncommon but serious reactions are angioedema (swelling of the face or throat) and changes in blood cells with inflammatory reactions of organs including the liver, kidney, and heart (‘eosinophilia and systemic symptoms’). Pregabalin produces dizziness in about 30% and somnolence in 23%. It can cause weight gain, pooling of fluid in the extremities, and allergic reactions, including angioedema. Antiepileptic drugs as a class may increase the risk of suicidal ideation or actions, starting as early as one week of treatment and lasting at least as long as the 24 weeks which have been studied.

Dependence: Abruptly stopping high doses of gabapentin can produce anxiety, disturbed sleep, confusional states, disorientation, and agitation. This has usually been associated with persons misusing the drug, but milder forms of withdrawal disturbance have been seen after therapeutic doses. Pregabalin, if stopped abruptly, can cause transient sleep disturbance, anxiety, diarrhea, nausea, or seizures. Both drugs should be tapered slowly before stopping. Pregabalin was classified as a Schedule V controlled substance by the D.E.A. in 2005.  Both gabapentin and pregabalin are listed as controlled substances in the U.K. Gabapentin is currently not a federally scheduled drug in the U.S., but is classified as Schedule V by several states. It is under review by the U.S. Food and Drug Administration, based on some suggestions of abuse. There is growing recognition that it is used recreationally, and some illicit heroin preparations contain gabapentin as a way of increasing the euphoric experience. It is estimated that gabapentin is misused in 15-22 percent of persons who abuse opioids.

Overdose: Overdoses of gabapentin of up to 35 gm have been reported to produce drowsiness, dizziness, coordination difficulties, diarrhea, and lowered blood pressure, and have generally not been fatal when taken alone by healthy persons. In Kentucky, one of the states in which it is now a scheduled drug, it appeared in one-third of fatal overdoses, which included overdoses of combinations of substances. There is less experience in this regard with pregabalin. During development, an accidental overdose of 8,000 mg taken alone occurred without significant medical complications. Like gabapentin, it is sometimes used with opiates, with toxic or even lethal results. Similarly, when in combination with alcohol or nervous system depressants, there is the possibility of greater toxicity.

Choosing gabapentin and pregabalin: These drugs are widely used off-label as an alternative to benzodiazepines for anxiety disorders. The speed of their onset of action has not been clearly established, but many clinicians have the impression that it is often within a few days, much shorter than that for antidepressants. They are also used to augment anti-anxiety effects in persons who have not responded to the use of antidepressants. Among the difficulties, as is often the case with off-label use, is the absence of very much long-term data.

In summary, gabapentinoids became popular as a treatment for anxiety because they were thought to be safer than other available drugs such as benzodiazepines, with an initial perceived lack of abuse potential.  Systematic studies showing benefits for anxiety are relatively limited, and as we have gained experience with these compounds, there is increasing evidence of recreational use and dependence, and a growing recognition of their side effect profiles.

Wallace B. Mendelson is a psychiatrist and author of Understanding Antidepressants and Understanding Medicines for Anxiety.

Image credit: Shutterstock.com

Prev

How online physician reviews can be fake news

July 30, 2019 Kevin 1
…
Next

4 tips to become a "nice" doctor

July 31, 2019 Kevin 2
…

Tagged as: Psychiatry

Post navigation

< Previous Post
How online physician reviews can be fake news
Next Post >
4 tips to become a "nice" doctor

ADVERTISEMENT

More by Wallace B. Mendelson, MD

  • Second-tier, off-label treatments for anxiety

    Wallace B. Mendelson, MD
  • Think beyond benzodiazepines for anxiety

    Wallace B. Mendelson, MD
  • How and why to treat sleep disturbance from depression

    Wallace B. Mendelson, MD

Related Posts

  • Second-tier, off-label treatments for anxiety

    Wallace B. Mendelson, MD
  • Think beyond benzodiazepines for anxiety

    Wallace B. Mendelson, MD
  • The art of off-label prescribing

    Hans Duvefelt, MD
  • Why the anti-vaxxer label makes this medical student uncomfortable

    Subha Mohan
  • Sleep and the medical profession have an uneasy relationship

    Yoo Jung Kim, MD
  • Medical school and the science of sleep

    Sarah Murad

More in Meds

  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • The food-drug interaction risks your doctor may be missing

    Frank Jumbe
  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why point-of-care ultrasound belongs in every emergency department triage [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why PSA levels alone shouldn’t define your prostate cancer risk

      Martina Ambardjieva, MD, PhD | Conditions
    • How to handle chronically late patients in your medical practice

      Neil Baum, MD | Physician
    • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

      Olumuyiwa Bamgbade, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • Why medicine must evolve to support modern physicians

      Ryan Nadelson, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why point-of-care ultrasound belongs in every emergency department triage [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why PSA levels alone shouldn’t define your prostate cancer risk

      Martina Ambardjieva, MD, PhD | Conditions
    • How to handle chronically late patients in your medical practice

      Neil Baum, MD | Physician
    • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

      Olumuyiwa Bamgbade, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • Why medicine must evolve to support modern physicians

      Ryan Nadelson, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Off-label use of gabapentin and pregabalin for anxiety
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...